NOX 4.76% 11.0¢ noxopharm limited

Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed, page-20

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,515 Posts.
    lightbulb Created with Sketch. 337
    The human body is obviously not a mouse - we obviously have size differences by multiples - imagine the poor mouse having a suppository! I get the human tumour but this can be grown in the lab why put them in a mouse - how is that relevant to a human? if the compound attacks the tumour in a test tube then what is the point of putting that tumour into a mouse who is then given the compound/s?
    I guess safety wise its a good idea to test it on a poor mouse before using it on a human but the human tumour is still a human tumour - it came from a human (presumably), putting it into a mouse with the differences in anatomy and physiology and diet and environment and DNA etc etc etc I would think is not a great indicator of how it would behave in a human - safety yes no argument. (having said that sometimes this is not the case in that what doesn't hurt a mouse can sometimes hurt a human as described in the below article)

    Why Drugs Tested in Mice Fail in Human Clinical Trials

    https://sitn.hms.harvard.edu/flash/2020/why-drugs-tested-in-mice-fail-in-human-clinical-trials/

    Last edited by Pbnewby: 13/08/21
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
11.0¢
Change
0.005(4.76%)
Mkt cap ! $32.14M
Open High Low Value Volume
11.0¢ 11.0¢ 10.0¢ $9.409K 87.00K

Buyers (Bids)

No. Vol. Price($)
1 49737 10.5¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 51289 1
View Market Depth
Last trade - 16.10pm 11/10/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.